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BACKGROUND
Bronchoscopic lung-volume reduction with the use of one-way endobronchial valves 
is a potential treatment for patients with severe emphysema. To date, the benefits 
have been modest but have been hypothesized to be much larger in patients without 
interlobar collateral ventilation than in those with collateral ventilation.
METHODS
We randomly assigned patients with severe emphysema and a confirmed absence of 
collateral ventilation to bronchoscopic endobronchial-valve treatment (EBV group) or 
to continued standard medical care (control group). Primary outcomes were 
changes from baseline to 6 months in forced expiratory volume in 1 second (FEV1), 
forced vital capacity (FVC), and 6-minute walk distance.
RESULTS
Eighty-four patients were recruited, of whom 16 were excluded because they had 
collateral ventilation (13 patients) or because lobar segments were inaccessible to 
the endobronchial valves (3 patients). The remaining 68 patients (mean [±SD] age, 
59±9 years; 46 were women) were randomly assigned to the EBV group (34 pa-
tients) or the control group (34). At baseline, the FEV1 and FVC were 29±7% and 
77±18% of the predicted values, respectively, and the 6-minute walk distance was 
374±86 m. Intention-to-treat analyses showed significantly greater improvements 
in the EBV group than in the control group from baseline to 6 months: the in-
crease in FEV1 was greater in the EBV group than in the control group by 140 ml 
(95% confidence interval [CI], 55 to 225), the increase in FVC was greater by 347 ml 
(95% CI, 107 to 588), and the increase in the 6-minute walk distance was greater 
by 74 m (95% CI, 47 to 100) (P<0.01 for all comparisons). By 6 months, 23 serious 
adverse events had been reported in the EBV group, as compared with 5 in the 
control group (P<0.001). One patient in the EBV group died. Serious treatment-
related adverse events in this group included pneumothorax (18% of patients) and 
events requiring valve replacement (12%) or removal (15%).
CONCLUSIONS
Endobronchial-valve treatment significantly improved pulmonary function and 
exercise capacity in patients with severe emphysema characterized by an absence 
of interlobar collateral ventilation. (Funded by the Netherlands Organization for 
Health Research and Development and the University Medical Center Groningen; 
Netherlands Trial Register number, NTR2876.)
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Bronchoscopic lung-volume reduc-tion with the use of one-way endobron-chial valves has emerged as a potential 
treatment for patients with severe emphysema. 
This treatment was previously investigated in the 
randomized, controlled Endobronchial Valve for 
Emphysema Palliation Trial (VENT),1 which 
showed significant but moderate improvements 
in forced expiratory volume in 1 second (FEV1): 
an increase from baseline of 4.3% (95% confi-
dence interval [CI], 1.4 to 7.2). Post hoc analyses 
of the VENT data suggested that endobronchial-
valve treatment might be more effective in pa-
tients who had a complete fissure (as compared 
with an incomplete fissure) between the lobe 
that was targeted for treatment and the adjacent 
lobe on high-resolution computed tomography 
(HRCT) and when endobronchial-valve treatment 
resulted in complete occlusion of the target lobe.1
A complete fissure on HRCT is a surrogate 
finding for the absence of interlobar collateral 
ventilation; if there is collateral ventilation, an 
occluded lobe can be reinflated through its col-
laterals.2 It is difficult to assess the complete-
ness of the fissure on HRCT in order to predict 
the absence of collateral ventilation, with con-
siderable interobserver variation.3 Temporary 
bronchoscopic lobar occlusion, achieved by infla-
tion of a balloon catheter in the lobar bronchus, 
is another way to assess collateral ventilation. 
When combined with HRCT, this method has 
been shown to increase the predictability of 
lung-volume reduction after endobronchial-valve 
treatment.4 We conducted a randomized, con-
trolled study, called STELVIO, to examine the 
effectiveness of endobronchial-valve treatment 
in patients with severe emphysema in whom the 
absence of collateral ventilation had been proved.
Me thods
Study Design and Oversight
This was a randomized, controlled study com-
paring endobronchial-valve treatment with stan-
dard medical care,5 with crossover at 6 months 
to endobronchial-valve treatment for patients as-
signed to standard medical care. The study was 
performed, in accordance with the provisions of 
the Declaration of Helsinki, at the University 
Medical Center Groningen (UMCG), in the Neth-
erlands, and was approved by the UMCG ethics 
committee. All patients gave written informed 
consent. All devices were obtained commercially 
from Pulmonx (all catheters at regular market 
prices and all valves at 50% of the market list 
price); Pulmonx was not involved in any part of 
the study.
Patients
Patients with emphysema who were older than 
35 years of age and had stopped smoking more 
than 6 months earlier were eligible for the study 
if they had a post-bronchodilator FEV1 that was 
less than 60% of the predicted value, total lung 
capacity (TLC) that was more than 100% of the 
predicted value, and residual volume that was 
more than 150% of the predicted value, with a 
score on the Modified Medical Research Council 
(mMRC) scale6 of more than 1 (on a scale of 
0 to 4, with higher scores indicating more severe 
dyspnea). An additional criterion for eligibility 
was a lobe that was determined to be a target for 
treatment, with a complete or nearly complete 
fissure between the target lobe and the adjacent 
lobe as visually judged on HRCT. The main ex-
clusion criteria were evidence of collateral venti-
lation in the target lobe and failure to achieve 
lobar occlusion with endobronchial valves, as 
noted below.
Randomization
We randomly assigned patients in a 1:1 ratio to 
receive endobronchial-valve treatment (EBV group) 
or standard care (control group), using a ran-
domization list that was computer-generated in 
blocks of four. The principal investigator and 
study personnel did not have access to the list. 
The generated codes were placed in opaque 
sealed envelopes, which were numbered sequen-
tially. After completion of baseline measurements 
(pulmonary-function tests, 6-minute walk dis-
tance, and questionnaires) and when study crite-
ria apart from bronchoscopy had been met, the 
assigned envelope was opened before bronchos-
copy in the presence of the patient and bron-
choscopist. Bronchoscopy was then performed, 
and patients with collateral ventilation or air-
ways unsuitable for endobronchial-valve place-
ment were excluded. When a patient was ex-
cluded, the treatment assignment was placed in 
a newly sealed envelope and inserted back into 
the randomization sequence.
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Procedures
Collateral ventilation was assessed by means of 
the Chartis system (Pulmonx) as previously de-
scribed.4 Briefly, during bronchoscopy (performed 
with a flexible bronchoscope [Olympus BF-1TQ180] 
with a 2.8-mm working channel) while the pa-
tient was under conscious sedation (with the 
administration of propofol and remifentanil), 
the target lobar airway was temporarily occluded 
by means of a balloon catheter, which blocks in-
spiratory flow but allows expiratory flow. A con-
tinuous expiratory flow through the catheter in-
dicates collateral ventilation, and a flow gradually 
declining to zero indicates no collateral venti-
lation. Zephyr endobronchial valves (Pulmonx) 
were placed in all segments or subsegments of 
the target lobe as previously described, with the 
patient under either general anesthesia or con-
scious sedation.1,4 Valve placement was performed 
during the initial bronchoscopic procedure for pa-
tients assigned to the EBV group and at 6 months 
for patients assigned to the control group.
Outcome Measures
Primary outcome measures were improvements 
from baseline to 6 months in FEV1, forced vital 
capacity (FVC), and 6-minute walk distance in 
the EBV group as compared with the control 
group. Secondary outcome measures, among 
patients who completed the study, were improve-
ments from baseline to 6 months in FEV1, forced 
vital capacity (FVC), 6-minute walk distance, the 
total score on the St. George’s Respiratory Ques-
tionnaire (SGRQ; scores range from 0 to 100, 
with higher scores indicating worse quality of 
life),7,8 the score on the Clinical COPD (chronic 
obstructive pulmonary disease) Questionnaire 
(CCQ; scores range from 0 to 6, with higher 
scores indicating worse functioning),9 and the 
total volume of the treated lobe on inspiratory 
HRCT. Clinical response was defined on the 
basis of established minimal clinically important 
differences from baseline (FEV1, a 10% increase
10; 
6-minute walk distance, a 26-m increase11; SGRQ 
score, a 4-point reduction8; CCQ score, a 0.4-point 
reduction9; total volume of the treated lobe, a 
350-ml reduction2; and residual volume, a 430-ml 
reduction12). Safety data were collected during the 
study. At baseline and at 1 month and 6 months 
of follow-up, the 6-minute walk test was per-
formed according to American Thoracic Society 
recommendations,13 and the SGRQ,7 CCQ,9 and 
mMRC6 scores were obtained. Spirometry, whole-
body plethysmography, and carbon monoxide 
diffusing capacity (measured with the Jaeger 
MasterScreen, CareFusion) were performed ac-
cording to American Thoracic Society–European 
Respiratory Society guidelines14,15 by assessors 
who were unaware of the study-group assign-
ments. HRCT was performed at baseline and at 
6 months after endobronchial-valve treatment. 
Target-lobe selection and fissure integrity were 
assessed visually on the baseline inspiratory 
HRCT scan (SOMATOM Sensation 64 eco, Siemens 
Healthcare; slice thickness, 1.0 mm) with the use 
of the AquariusNET viewer V4.4.7.85 (TeraRecon). 
After study completion, computerized quantifi-
cations were performed on the HRCT data set 
(Thirona Lung Quantification, version 15.01 
[Thirona]).16,17 We calculated lobar volumes and 
the percentage of voxels of less than −950 Houns-
field units (an indicator of the fraction of em-
physematous lung). We classified the distribution 
of emphysema in the treated lung as homoge-
neous if the destruction scores for the upper and 
lower lobes differed by less than 15% and as het-
erogeneous if the scores differed by 15% or more.
Statistical Analysis
The initial sample size was based on the avail-
able post hoc analyses of the active treatment 
groups in the VENT, international VENT, and 
Chartis trial1,2,4 and on our preliminary findings. 
With an alpha level at 5% and a beta level at 
20%, we calculated that we would need to ran-
domly assign 28 patients to the study groups 
(14 per group), all of whom could be fully evalu-
ated with respect to the change in the percent-
age of the predicted FEV1. A subsequent interim 
analysis for safety, withdrawal from the study, 
and assessment of the accuracy of FEV1 assump-
tions showed a higher pneumothorax rate and a 
lower mean difference from baseline for the 
percentage of the predicted FEV1 than we had 
assumed. To account for these findings, 68 pa-
tients were deemed necessary for randomiza-
tion. A two-sample t-test and Fisher’s exact test 
were performed to test for differences between 
groups at baseline. Intention-to-treat analyses 
were performed on the primary end points; if 
there were no available data after study exit, 
then multiple imputation was used for missing 
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data. Primary, secondary, and other efficacy out-
comes were also evaluated in analyses restricted 
to patients who completed the study. Paired t-tests 
were used, or in the absence of a normal distri-
bution, the Wilcoxon signed-rank test was used, 
to compare the groups with respect to changes 
from baseline to 6 months in study outcomes. 
Bonferroni correction was performed for multi-
ple comparisons for the three primary end 
points. P values of less than 0.0167, for primary 
Characteristic
EBV Group 
(N = 34)
Control Group 
(N = 34)
Female sex — no. (%) 18 (53) 28 (82)
Age — yr 58±10 59±8
Body-mass index† 24.1±3.5 24.2±4.0
Cigarette smoking — no. of pack-yr 37±18 35±19
Lung function
FEV1
Liters 0.86±0.30 0.79±0.27
% of predicted value 29±7 29±8
FVC
Liters 2.80±0.83 2.50±0.90
% of predicted value 78±16 77±20
RV
Liters 4.64±1.31 4.43±0.72
% of predicted value 216±36 220±32
TLC
Liters 7.85±1.54 7.31±1.20
% of predicted value 130±13 133±10
Ratio of RV to TLC — % 59±9 61±8
Carbon monoxide diffusing capacity
Milliters of carbon monoxide/min/mm Hg 10.4±3.2 9.8±2.5
% of predicted value 38.7±9.1 39.0±9.7
Arterial blood gas — mm Hg‡
Partial pressure of oxygen 69±12 69±9
Partial pressure of carbon dioxide 38±6 38±4
Distance on 6-min walk test — m 372±90 377±84
Quality-of-life scores — no. of points§
St. George’s Respiratory Questionnaire 59.1±13.7 59.3±11.6
Modified Medical Research Council scale 2.7±0.8 2.7±0.6
Clinical COPD Questionnaire 2.9±0.8 2.7±0.6
HRCT findings¶
Target-lobe volume — ml 1993±742 1716±555
Target-lobe voxels below −950 Hounsfield units — % 47.7±8.2 45.7±7.3
Emphysema distribution — no. (%)
Homogeneous 18 (53) 18 (53)
Heterogeneous 16 (47) 16 (47)
Table 1. Baseline Characteristics of the Patients.*
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outcomes, and less than 0.05, for secondary 
outcomes, were considered to indicate statistical 
significance. For each outcome, response rates 
were calculated by counting the number of pa-
tients who had a change from baseline that met 
the criterion for a minimal clinically important 
difference. Fisher’s exact test was performed for 
calculations of between-group differences in out-
comes and adverse events. SPSS Statistics, ver-
sion 22 (IBM), was used for all analyses. For 
detailed information about study methods, in-
cluding the statistical analysis, see the Supple-
mentary Appendix, available with the full text of 
this article at NEJM.org.
R esult s
Study Patients
The study was conducted between June 2011 
and November 2014. Eighty-four patients were 
screened and underwent baseline bronchoscopy. 
Of these patients, 16 were excluded because they 
had collateral ventilation (13 patients) or be-
cause the airway anatomy was not suitable for 
endobronchial-valve placement (3), resulting in 
a total of 68 patients who underwent random-
ization (Fig. S1 in the Supplementary Appendix). 
A total of 9 patients in the EBV group and 1 in the 
control group were not able to complete 6 months 
of follow-up. Among the patients in the control 
group who crossed over to endobronchial-valve 
treatment at 6 months, lobar occlusion was not 
possible in 3 patients because the airway anatomy 
was not suitable for endobronchial-valve place-
ment, and this had not been detected during 
baseline bronchoscopy. Baseline characteristics 
were similar in the two study groups except that 
there were more women in the control group than 
in the EBV group (28 vs. 18, P = 0.01) (Table 1).
Procedure
Endobronchial-valve treatment was performed in 
34 patients in the first component of the study. 
A median of four endobronchial valves (range, 
two to seven) were placed per patient, with a me-
dian procedure time of 18 minutes (range, 6 to 
51). The median post-treatment hospital stay was 
1 day (range, 1 to 13). For a detailed description 
of the procedure, see Section 9 in the Supple-
mentary Appendix.
Primary Outcomes
In the intention-to-treat population, changes from 
baseline to 6 months in FEV1, FVC, and 6-minute 
Characteristic
EBV Group 
(N = 34)
Control Group 
(N = 34)
Medical history — no. (%)
α1-Antitrypsin deficiency 4 (12) 3 (9)
Previous pneumothorax 2 (6) 1 (3)
Regular physical activity under professional supervision — no. (%)‖ 27 (79) 26 (76)
*  Plus–minus values are means ±SD. There were no significant differences in baseline characteristics between the two 
study groups (P>0.05) except for female sex (P = 0.01). EBV denotes endobronchial valve, FEV1 forced expiratory volume 
in 1 second, FVC forced vital capacity, HRCT high-resolution computed tomography, RV residual volume, and TLC total 
lung capacity.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  The partial pressure of oxygen and the partial pressure of carbon dioxide were measured while the patient was breath-
ing ambient air.
§  Scores on the St. George’s Respiratory Questionnaire range from 0 to 100, with higher scores indicating worse quality 
of life. Scores on the Modified Medical Research Council scale range from 0 to 4, with higher scores indicating more 
severe dyspnea. Scores on the Clinical COPD (chronic obstructive pulmonary disease) Questionnaire range from 0 to 6, 
with higher scores indicating worse functioning.
¶  Emphysema distribution was assessed as the difference in destruction (percentage of voxels of less than −950 Hounsfield 
units) between the upper and lower lobes in the lung that underwent endobronchial-valve treatment, with a difference 
of less than 15% defined as homogeneous and a difference of 15% or more defined as heterogeneous.
‖  Patients with regular supervised physical activity had completed a pulmonary rehabilitation program, were receiving 
maintenance physiotherapy twice a week for their chronic obstructive pulmonary disease, or both. No changes were 
made in supervised physical activity before or after randomization.
Table 1. (Continued.)
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walk distance were significantly greater in the 
EBV group than in the control group (P<0.01 for 
all comparisons) (Table 2 and Fig. 1).
Secondary Outcomes
Analyses of data for patients who completed the 
study (25 patients in the EBV group and 33 in 
the control group) showed significant improve-
ments in the secondary outcome measures from 
baseline to 6 months in the EBV group as com-
pared with the control group: the increase in 
FEV1 was greater in the EBV group than in the 
control group by 191 ml (95% CI, 109 to 272), 
the increase in FVC was greater by 442 ml (95% 
CI, 215 to 668), and the increase in the 6-minute 
walk distance was greater by 106 m (95% CI, 80 
to 133) (P<0.001 for all between-group compari-
sons); improvements were also seen in SGRQ 
scores, with a 14.7-point greater reduction in the 
EBV group than in the control group (95% CI, 
−21.8 to −7.6; P<0.001), and in CCQ scores, with 
a 0.74-point greater reduction in the EBV group 
than in the control group (95% CI, −1.20 to 
−0.27; P = 0.002). In the EBV group, the median 
change from baseline in target lobar volume on 
HRCT was a reduction of 1366 ml (range, −3604 
to −28; P<0.001) (Fig. 1, and Table S4 in the 
Supplementary Appendix). Significantly more 
patients in the EBV group than in the control 
group had changes from baseline measures that 
exceeded the established minimal clinically im-
portant difference (P<0.001 for all comparisons) 
(Table S6 in Supplementary Appendix).
Among patients who completed the study, 
those who crossed over to endobronchial-valve 
treatment at 6 months had improvements that 
were very similar to the improvements in the EBV 
group (Table S5 in the Supplementary Appen-
dix). Post hoc analysis of HRCT findings in pa-
tients who completed the study showed that for 
patients with heterogeneous emphysema and for 
those with homogeneous emphysema, there was 
a significant between-group difference in FEV1, 
6-minute walk distance, residual volume, and 
SGRQ score in favor of the EBV group at 6 months 
of follow-up. The effects tended to be larger in 
patients with heterogeneous emphysema than in 
those with homogeneous emphysema (Table S7 
in the Supplementary Appendix).
Adverse Events
One pneumothorax was detected in 84 assess-
ments that were performed by means of the 
Chartis system. In 7 of the 34 patients in the 
EBV group (21%), the endobronchial valves were 
associated with unacceptable adverse events and 
had to be removed. There were 23 serious ad-
verse events in the EBV group, as compared with 
5 in the control group (P<0.001) (Table 3). In the 
EBV group, treatment-related serious adverse 
events included pneumothorax (in 18% of pa-
tients), other events requiring valve replacement 
(in 12% of patients) or valve removal (in 15% of 
patients), and 1 death due to end-stage COPD 
with respiratory failure 58 days after treatment. 
All adverse events are listed in Tables S9 and S10 
in the Supplementary Appendix.
Pneumothorax
In the EBV group, the frequency of pneumotho-
rax was 18% (6 of 34 patients). In 1 patient, the 
pneumothorax resolved spontaneously; in 5 pa-
tients, insertion of a chest tube was required, 
with temporary removal of endobronchial valves 
in 1 patient to promote pneumothorax healing 
and permanent removal of all valves in 2 pa-
tients because of recurrent pneumothorax, after 
which resolution occurred. No surgical proce-
dures were used to control the pneumothorax.
Repeat Bronchoscopy
Bronchoscopy was repeated in 12 of 34 patients 
in the EBV group (35%). Reasons for repeat 
bronchoscopy were permanent removal of endo-
bronchial valves because of recurrent pneumo-
thorax (in 2 patients), torsion of the left-lower-
lobe bronchus after left-upper-lobe treatment (in 2), 
pneumonia distal to the valves (in 1), and mark-
edly increased dyspnea and sputum production 
without a treatment benefit, as perceived by the 
patient (in 2); and temporary removal of endo-
bronchial valves to promote healing of a pneu-
mothorax, with valve replacement after 2 months 
(in 1). Other reasons for repeat bronchoscopy 
were valve replacement due to migration (in 2), 
valve dislocation because of granulation-tissue 
formation (in 1), and persistent cough, with valve 
replacement in the other lobe (in 1). (For addi-
tional information, see Table S9 in the Supple-
mentary Appendix.)
Discussion
We found that endobronchial-valve treatment in 
patients with emphysema and a proven absence 
of interlobar collateral ventilation provided a 
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measurable clinical benefit, with significantly 
improved lung function, exercise capacity, and 
quality of life, as compared with usual care. The 
reduction in lung volume with subsequent posi-
tive outcomes was accompanied by adverse ef-
fects, mainly pneumothorax, which was man-
aged by means of regular care (including 
chest-tube drainage) but sometimes required re-
peated bronchoscopy. The endobronchial valves 
were retained throughout the 6-month study 
period in 79% of the initially treated patients.
This prospective, randomized, controlled trial 
confirmed the results of open-label and post hoc 
studies assessing responses to endobronchial-
valve treatment.1,2,4,18 In the VENT,1 the overall 
benefits were moderate, but post hoc analysis 
showed a significantly greater improvement in 
FEV1 in patients with a complete fissure, which 
indicates an absence of collateral ventilation, 
than in those with an incomplete fissure. A pre-
vious multicenter study validating the Chartis 
system, which measures collateral ventilation, 
showed that treatment success was not associ-
ated with the method of fissure assessment (i.e., 
fissure assessment by means of highly dedicated 
HRCT vs. assessment by means of the Chartis 
system).4 However, the current results show that 
when collateral ventilation is assessed, the over-
all outcome of treatment is positive. In our study, 
84 patients were preselected on the basis of hav-
ing complete or nearly complete fissures on 
HRCT scans, with an additional 13 of those pa-
tients (15%) excluded on the basis of assessment 
by means of the Chartis system. We think it is 
reasonable to speculate that these patients with 
collateral ventilation would not have had a benefit 
from endobronchial-valve treatment.
Among the patients who completed the study, 
there was a significant benefit of the treatment 
on FEV1, residual volume, 6-minute walk dis-
tance, and scores on the CCQ and SGRQ, with 
effect sizes all well above the established mini-
mal clinically important differences for these 
variables (Fig. 1). The improvements with endo-
bronchial-valve treatment tended to be larger in 
patients with emphysema that was heteroge-
neous than in those with emphysema that was 
homogeneous, although we observed improve-
ments in both subgroups, a finding that was 
also suggested by post hoc analysis of the data 
from the international VENT.2 Although compari-
sons among studies is difficult, it is interesting 
to note that the improvements we found were of 
greater magnitude than those noted with phar-
macologic treatment in comparable patients and 
were similar to improvements with surgical 
lung-volume reduction, but with significantly less 
morbidity.19,20
Even though the trial was randomized and 
controlled, the large improvements in SGRQ 
Variable
EBV Group 
(N = 34)
Control Group 
(N = 34)
Between-Group 
Difference P Value
Change in FEV1
Milliliters (95% CI) 161 (80 to 242) 21 (−9 to 52) 140 (55 to 225) 0.002
Percentage (95% CI) 20.9 (11.1 to 30.7) 3.1 (−0.4 to 6.6) 17.8 (7.6 to 28.0) 0.001
Response rate — % 59 24 — 0.003
Change in FVC
Milliliters (95% CI) 416 (201 to 631) 69 (−50 to 187) 347 (107 to 588) 0.005
Percentage (95% CI) 18.3 (9.3 to 27.3) 4.0 (−0.7 to 8.6) 14.4 (4.4 to 24.3) 0.005
Change in distance on 6-min walk test
Meters (95% CI) 60 (35 to 85) −14 (−25 to −3) 74 (47 to 100) <0.001
Percentage (95% CI) 19.6 (10.4 to 28.9) −3.6 (−6.9 to −0.4) 23.3 (13.6 to 32.9) <0.001
Response rate — % 59 6 — <0.001
*  Paired t-tests were used to calculate within-group mean differences in changes from baseline to 6 months, P values, and 95% confidence 
 intervals. Two-sample t-tests or, in the absence of a normal distribution, Wilcoxon signed-rank tests were used to calculate between-group 
mean differences, P values, and 95% confidence intervals. Fisher’s exact test was used to calculate the between-group difference in re-
sponse rates. Response rates were calculated by counting the number of patients for whom the change at 6 months met or exceeded the 
minimal clinically important difference for FEV1 (>10%)10 and the 6-minute walk test (>26 m).11
Table 2. Mean Change from Baseline to 6 Months of Follow-up in Primary Efficacy Outcomes in the Intention-to-Treat Population.*
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Figure 1. Primary and Secondary Efficacy Outcomes in the Study Groups.
Shown are primary outcomes in the intention-to-treat population (Panel A) and secondary outcomes among patients 
who completed the study (Panel B), according to the assigned study group (endobronchial-valve [EBV] group or con-
trol group). Scores on the St. George’s Respiratory Questionnaire (SGRQ) range from 0 to 100, with higher scores 
indicating worse quality of life. Scores on the Clinical COPD (chronic obstructive pulmonary disease) Questionnaire 
(CCQ) range from 0 to 6, with higher scores indicating worse functioning. Horizontal lines represent the minimal 
clinically important difference (MCID) for the following outcomes: forced expiratory volume in 1 second (FEV1),10 an 
increase of 100 ml; 6-minute walk distance (6MWD),11 an increase of 26 m; SGRQ score,8 a reduction of 4 points, 
CCQ score,9 a reduction of 0.4 points; and residual volume (RV),12 a reduction of 430 ml. T bars indicate 95% confi-
dence intervals, and FVC denotes forced vital capacity.
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scores could have been influenced by the open-
label design. A previous trial of bronchoscopic 
intervention, in which a sham control was used, 
showed that placebo effects were limited in pa-
tients with severe COPD.21 Two other sources of 
potential bias should be considered: both patients 
and bronchoscopists were aware of the treat-
ment assignment at the time of bronchoscopy, 
and the revealed treatment assignments for the 
patients with collateral ventilation or unsuitable 
airways for endobronchial-valve placement were 
put back in the randomization sequence in newly 
Event
EBV Group 
(N = 34)
Control Group 
(N = 34) P Value†
no. (%)
Total no. of serious events 23 5 <0.001
Pulmonary events
Death 1 (3)‡ 0 1.00
COPD exacerbation with hospitalization 4 (12) 2 (6) 0.67
Pneumonia 2 (6) 1 (3) 1.00
Pneumothorax 6 (18) 0 0.02
Resolved ≤14 days after onset, without drainage 1 (3) 0 1.00
Resolved ≤14 days after onset, with drainage 2 (6) 0 0.49
Required temporary valve removal 1 (3)§ NA NA
Required permanent valve removal because of recurrent 
pneumothorax
1 (3) NA NA
Required permanent valve removal, after temporary 
removal and reimplantation, because of recurrent 
pneumothorax
1 (3) NA NA
Other EBV-related events requiring permanent removal of 
all valves
Torsion of the bronchus 2 (6)¶ NA NA
Pneumonia distal to valve 1 (3)‖ NA NA
Increased sputum, dyspnea, or coughing without patient-
perceived treatment benefit
2 (6) NA NA
Other EBV-related events requiring valve replacement
Valve migration 2 (6) NA NA
Valve expectoration 0 NA NA
Valve dislocation due to formation of granulation tissue 1 (3) NA NA
Increased sputum, dyspnea, or coughing 1 (3) NA NA
Stroke 1 (3) 2 (6) 1.00
*  Serious adverse events were all adverse events that were fatal, required or prolonged hospitalization, caused substan-
tial risk of death at the time of the event, resulted in permanent impairment of a body function, or required medical or 
surgical intervention to prevent permanent impairment of a body function. Nonserious adverse events during 6 months 
of follow-up are listed in Table S10 in the Supplementary Appendix. NA denotes not applicable.
†  A two-sided Fisher’s exact test was used to calculate the difference in adverse events between the EBV group and the 
control group.
‡  The patient died from end-stage chronic obstructive pulmonary disease with respiratory failure 58 days after endobron-
chial-valve treatment.
§  The valve was removed temporarily to expand the target lobe; the pneumothorax resolved, and at 49 days, the valve 
was reimplanted.
¶  Both patients had low oxygen saturation and dyspnea after endobronchial-valve treatment in the left upper lobe; CT 
scans confirmed torsion of the left lower bronchus. In both cases, the valves were removed at 14 days, with complete 
recovery after removal.
‖  Postobstruction pneumonia developed in the treated lobe 163 days after treatment; valves were removed, and the pa-
tient recovered.
Table 3. Serious Adverse Events during 6 Months of Follow-up.*
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sealed envelopes. However, baseline characteris-
tics were similar in the two study groups, except 
for sex distribution. In addition, the results for 
the patients in the control group who crossed 
over to endobronchial-valve treatment at 6 months 
were similar to those for the original EBV group.
Pneumothorax, which was the most frequent 
adverse event, is thought to be due to a rapid 
shift in lung volumes caused by the rupture of 
blebs or bullae, the rupture of parenchyma due 
to pleural adhesions, or the response to baro-
trauma.22 The observed frequency of pneumo-
thorax (18%) in our study was higher than the 
frequencies reported in earlier trials (VENT in 
2010, 4%1; Chartis trial in 2013, 8%4) but was 
similar to the frequency in an analysis of Ger-
man data from 2014 (23%23). This increase in 
the frequency of pneumothorax is probably the 
result of more successful execution of endobron-
chial-valve treatment (resulting in a higher per-
centage of patients having a significant reduction 
in lobar volume) and patient selection (i.e., patients 
without collateral flow). All cases of pneumo-
thorax in the EBV group occurred within 1 day 
after endobronchial-valve treatment, when the 
patients were still hospitalized. Because a pneu-
mothorax is a potentially life-threatening com-
plication in patients with severe emphysema, we 
found that close monitoring of patients after 
endobronchial-valve treatment, including moni-
toring after discharge, was crucial. All cases of 
pneumothorax in our study were managed ac-
cording to published guidelines.22,24
Repeat bronchoscopy is sometimes necessary 
to replace or temporarily or permanently remove 
endobronchial valves. Reasons to do so include 
loss of initial lung-volume reduction due to for-
mation of granulation tissue or valve migration. 
Previous studies postulated that endobronchial-
valve treatment is fully reversible and does not 
preclude future therapeutic options.1,2,4 Our study 
provides confirmation of this view, since all 
patients in whom endobronchial valves were re-
moved recovered without further side effects.
In conclusion, we found that in patients with 
severe emphysema who were preselected on the 
basis of a proven absence of interlobar collateral 
ventilation, endobronchial-valve treatment im-
proved pulmonary function, exercise capacity, and 
quality of life, even when we considered patients 
in whom valve removal was required. Adverse 
events, including potentially life-threatening 
events, occurred and required careful follow-up.
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